Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:MGNX

MacroGenics Q3 2026 Earnings Date & Estimates

MacroGenics logo
$3.25 -0.12 (-3.56%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$3.24 0.00 (-0.15%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MacroGenics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from MacroGenics in Q3 2026

MacroGenics is expected to post earnings of -$0.10 per share on revenue of $39.18 million. In the same quarter a year earlier MacroGenics reported $0.27 per share on revenue of $72.84 million. MacroGenics last reported on August 13, 2026, posting $0.31 per share and beating the -$0.0779 consensus estimate. MacroGenics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.10
Expected Revenue
$39.18 million
Prior-Year EPS
$0.27
Prior-Year Revenue
$72.84 million
Expected EPS Growth
-137.0%
Expected Revenue Growth
-46.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.31 (Beat by +$0.3879)
Last Quarter Revenue
$32.83 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

MacroGenics Q3 2026 Earnings FAQ

MacroGenics (NASDAQ:MGNX) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

MacroGenics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect MacroGenics to post earnings of -$0.10 per share for Q3 2026.

The consensus revenue estimate for MacroGenics is $39.18 million for Q3 2026.

MacroGenics Earnings Headlines

MacroGenics, Inc. Announces First Patient Dosed In Phase 1 Study Of MGC030 In Patients With Advanced Solid Tumors
October 16 at 5:30 AM  |  marketscreener.comM
MacroGenics Says First Patient Dosed in Phase 1 Study of MGC030 for Advanced Solid Tumors
October 15 at 5:32 PM  |  marketscreener.comM
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
October 17 at 1:00 AM  |  Base Camp Trading (Ad)
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
October 15 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/15/3382129/0/en/macrogenics-announces-first-patient-dosed-in-phase-1-study-of-mgc030-in-patients-with-advanced-solid-tumors.html
Financial Review: Madrigal Pharmaceuticals (NASDAQ:MDGL) & MacroGenics (NASDAQ:MGNX)
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106040
MacroGenics consensus price target rises 12% to $9.52
September 14, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/macrogenics-consensus-price-target-rises-12-to-952/ar-AA2cbGur
See More MacroGenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MacroGenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MacroGenics and other key companies, straight to your email.

About MacroGenics

MacroGenics (NASDAQ:MGNX) is a biopharmaceutical company focused on developing antibody-based therapies for cancer and other serious diseases. Based in Rockville, Maryland, the company uses its proprietary DART platform to design molecules intended to direct the immune system against diseased cells, along with technologies for modifying antibody activity and half-life.

MacroGenics’ commercial products include MARGENZA (margetuximab-cmkb), an antibody approved in the United States for certain patients with HER2-positive metastatic breast cancer, and ZYNYZ (retifanlimab-dlwr), an immune checkpoint inhibitor approved for adults with metastatic or recurrent Merkel cell carcinoma. The company also maintains a pipeline of investigational therapies for oncology and autoimmune indications.

Founded in 2000, MacroGenics conducts research and clinical development activities in the United States and works with international pharmaceutical partners to develop and commercialize certain products in additional markets. The company was founded by Scott Koenig, who has served as its chief executive officer and has led its development of antibody-based therapeutics.

View MacroGenics Profile
Earnings Tools